-
Analyst Opinions
NewUnited Kingdom (UK) Bancassurance Distribution Dynamics and Future Market, 2023 Update
United Kingdom (UK) Bancassurance Distribution Market Overview Bancassurance represents a strategic alliance between banks and insurance companies, designed to offer customers the convenience of purchasing insurance products in conjunction with banking services. The banking channel accounts for the highest share of total personal and commercial lines distribution in 2023. App purchases through the bank channel increased with no other channel recording a higher proportion of purchases via apps. This could be because of banks’ intensified focus on digitalization, resulting in...
-
Company Insights
Innovation and Patenting activity of u-blox Holding AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of u-blox Holding AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Follicular Lymphoma Drug Details: SH-748 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – U-87 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - U-87 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.U-87 in Pancreatic Cancer Drug Details:U-87 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SH-748 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Marginal Zone B-cell Lymphoma Drug Details: SH-748 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Patritumab Deruxtecan in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Patritumab Deruxtecan in Metastatic Breast Cancer Drug Details: Patritumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rebyota in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebyota in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebyota in Crohn's Disease (Regional Enteritis) Drug Details: Fecal microbiota,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Patritumab Deruxtecan in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Patritumab Deruxtecan in Non-Small Cell Lung Cancer Drug...